english.prescrire.org > Prescrire International > N°188 - December 2017

n°188

December 2017

Issue Contents
Editorial

Free  From mother to child

p.283

Marketing Authorisations


Ivacaftor (Kalydeco°) and cystic fibrosis

p.285-286
Uncertain harm-benefit balance

Ivacaftor + lumacaftor (Orkambi°) and cystic fibrosis

p.287-289
A harm-benefit balance that requires further investigation

Bevacizumab (Avastin°) for first-line treatment of certain types of lung cancer

p.289
It does not prolong survival but it exposes to more adverse effects

Daratumumab (Darzalex°) monotherapy in relapsed and refractory multiple myeloma

p.290-291
No evidence of efficacy

Brivaracetam (Briviact°) and partial seizures

p.292-293
A commercial ploy with a levetiracetam "me-too"

INN Common stem: -verine, -verium

p.293

Adverse Effects


Free  Valproic acid during pregnancy: assessment of malformations in France

p.294

Short-term corticosteroid treatment: fractures, thrombosis and infections

p.295

Apremilast: suicide risk

p.295

Chlorhexidine: anaphylaxis following skin application

p.296

Quinine and cramps: increased mortality

p.296

Reviews


Moderate intensity nociceptive pain in adults

p.297-300

Type 2 diabetes

p.300-301
Prevention through dietary modification and physical activity

Outlook


Making rational choices about drug treatment while breast-feeding

p.302-306

Inset. Breast-feeding and drugs: sources of information

p.304

Induction of labour: still inadequate provision of information, and women's consent not always obtained

p.306-307

Letters to Prescrire's editors: domperidone and sudden cardiac death

p.307

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe